Windham Capital Partners is an investment firm that focuses on investing in HealthTech companies. The company aims to invest in technologies that have the potential to save lives and significantly impact the healthcare industry.

Windham Capital Partners

Windham Capital Partners is a New York City based growth equity firm focused on healthcare, with particular emphasis on therapeutic medical technology and digital health. We have a small, highly focused team of managers who enjoy close relationships with strategics, leading venture capital firms, and innovators and entrepreneurs in the healthcare industry.

Windham Capital Partners (#LSIEurope24 Investor) is a growth equity firm based in New York City, specializing in healthcare investments, particularly in therapeutic medical technology and digital health. 

They assess a company’s likelihood of success based on the 3 following standards:

1. The Leadership Team
• has the right experience, knowledge, expertise and resources
• is honest and realistic about the challenges the company faces

2. The Company
• is beyond the concept development stage
• addresses a large unmet need in healthcare
• addresses a large market and focused on “the next big thing”
• has generated impressive data demonstrating its technology or product works
• understands healthcare economics and can articulate a clear value proposition

3. The Technology or Procedure
• is “evidence-based”
• is either transformative, that is, it offers a totally new way to approach a problem, or clearly superior to any existing product
• is free of intellectual property barriers

Windham Capital Partners portfolio includes companies like:
• Andros (Jeff Fritz)
• Earlens Corporation (#LSIAlumni - Bill Facteau)
• Neuspera Medical Inc. (LSI Alumni - Steffen Hovard)
• Nuvaira, Inc. (Dennis Wahr M.D.)
• among others

We’re thrilled to welcome David Kereiakes, Managing Partner at Windham Capital Partners to LSI Europe ‘24 this September 16-20th in Sintra, Portugal.

Want to see what other investors are joining us at LSI Europe ‘24? Head over to our website to see a preview of the 100+ confirmed investors.

Congrats to the SubjectWell team and welcome to new partners WindRose Health Investors. We remain excited for the continued success and impact SubjectWell will have in accelerating drug development and enhancing patient access to clinical trials, especially diverse populations.

Meeting patients outside of the four walls of a clinic, physically, digitally, and emotionally, is critical to ensuring successful value-based care programs and improving quality outcomes. Jason Helgerson, Windham’s Senior Advisor, and Glen Moller, CEO of Windham portfolio company, Upward Health, team up to outline initiatives that are effectively engaging patients in their healthcare, and ones that require continued development. Check out the article co-authored by experts in value-based care. 

https://lnkd.in/gE_CWbJN

We are excited to announce today that FDA has approved expanded labeling for Barostim, incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. 
 
“We are very pleased to receive this important validation from FDA of the long-term results of the post-market phase of the BeAT-HF clinical trial and excited we can now share this data with physicians and patients,” said Nadim Yared, CVRx CEO

Read the PR here: 
https://lnkd.in/ghM6tExk

We pride ourselves on investing in great people building great companies – Congrats to Amit Etkin and the Alto Neuroscience team for a key financing milestone to support the development of important therapies in psychiatry.

Vergent Bioscience recently started their VISUALIZE study, a multi-center study to assess the potential of VGT-309. 

#tumorvisualization #lungcancer

COM:WINDHAMVP

Windham Capital Partners

Analysis Not Available